JP2023550191A - Ｄｒ４および／またはｄｒ５を標的とするポリペプチドならびに関連する組成物および方法 - Google Patents

Ｄｒ４および／またはｄｒ５を標的とするポリペプチドならびに関連する組成物および方法 Download PDF

Info

Publication number
JP2023550191A
JP2023550191A JP2023531563A JP2023531563A JP2023550191A JP 2023550191 A JP2023550191 A JP 2023550191A JP 2023531563 A JP2023531563 A JP 2023531563A JP 2023531563 A JP2023531563 A JP 2023531563A JP 2023550191 A JP2023550191 A JP 2023550191A
Authority
JP
Japan
Prior art keywords
nanocage
fusion protein
monomer
fragment
antigen binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023531563A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023550191A5 (https=
Inventor
ジャン－フィリップ ジュリアン，
ディエス， エドゥルネ ルハス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hospital for Sick Children HSC
Original Assignee
Hospital for Sick Children HSC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hospital for Sick Children HSC filed Critical Hospital for Sick Children HSC
Publication of JP2023550191A publication Critical patent/JP2023550191A/ja
Publication of JP2023550191A5 publication Critical patent/JP2023550191A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/735—Fusion polypeptide containing domain for protein-protein interaction containing a domain for self-assembly, e.g. a viral coat protein (includes phage display)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2023531563A 2020-11-25 2021-11-25 Ｄｒ４および／またはｄｒ５を標的とするポリペプチドならびに関連する組成物および方法 Pending JP2023550191A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063118306P 2020-11-25 2020-11-25
US63/118,306 2020-11-25
PCT/CA2021/051690 WO2022109743A1 (en) 2020-11-25 2021-11-25 Polypeptides targeting dr4 and/or dr5 and related compositions and methods

Publications (2)

Publication Number Publication Date
JP2023550191A true JP2023550191A (ja) 2023-11-30
JP2023550191A5 JP2023550191A5 (https=) 2024-12-02

Family

ID=81753696

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023531563A Pending JP2023550191A (ja) 2020-11-25 2021-11-25 Ｄｒ４および／またはｄｒ５を標的とするポリペプチドならびに関連する組成物および方法

Country Status (9)

Country Link
US (1) US20240182544A1 (https=)
EP (1) EP4251654A4 (https=)
JP (1) JP2023550191A (https=)
KR (1) KR20230116833A (https=)
CN (1) CN116917339A (https=)
AU (1) AU2021386892A1 (https=)
CA (1) CA3202378A1 (https=)
MX (1) MX2023006148A (https=)
WO (1) WO2022109743A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240101550A9 (ko) * 2021-09-13 2025-12-10 더 호스피탈 포 식 칠드런 암 치료용 dr5-표적화 다중체
KR20250135167A (ko) * 2022-09-11 2025-09-12 래디언트 바이오테라퓨틱스 인크. 다중체를 사용하는 화학요법-내성 종양의 치료

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019502653A (ja) * 2015-10-30 2019-01-31 ギャラクシー バイオテック， エルエルシーＧａｌａｘｙ Ｂｉｏｔｅｃｈ， Ｌｌｃ デスレセプター４及びデスレセプター５に結合する非常に強力な抗体
WO2019023811A1 (en) * 2017-08-04 2019-02-07 The Hospital For Sick Children NANOPARTICLE PLATFORM FOR ANTIBODY AND VACCINE DELIVERY
WO2020220044A2 (en) * 2019-04-25 2020-10-29 Hodge Curtis D Self-assembling protein nanocage decorated with antibodies (sapna) and parts thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019502653A (ja) * 2015-10-30 2019-01-31 ギャラクシー バイオテック， エルエルシーＧａｌａｘｙ Ｂｉｏｔｅｃｈ， Ｌｌｃ デスレセプター４及びデスレセプター５に結合する非常に強力な抗体
WO2019023811A1 (en) * 2017-08-04 2019-02-07 The Hospital For Sick Children NANOPARTICLE PLATFORM FOR ANTIBODY AND VACCINE DELIVERY
WO2020220044A2 (en) * 2019-04-25 2020-10-29 Hodge Curtis D Self-assembling protein nanocage decorated with antibodies (sapna) and parts thereof

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ANTIBODIES, vol. 6, no. 4, JPN6025043709, 2017, pages 16 - 1, ISSN: 0005715605 *
BIOMATERIALS, vol. 180, JPN6025043708, 2018, pages 67 - 77, ISSN: 0005715604 *
SCIENTIFIC REPORTS, vol. Vol.10, Article number: 19997, JPN6025043707, 17 November 2020 (2020-11-17), pages 1 - 17, ISSN: 0005715603 *

Also Published As

Publication number Publication date
CN116917339A (zh) 2023-10-20
CA3202378A1 (en) 2022-06-02
AU2021386892A1 (en) 2023-06-22
AU2021386892A9 (en) 2024-08-08
EP4251654A1 (en) 2023-10-04
MX2023006148A (es) 2023-08-07
US20240182544A1 (en) 2024-06-06
WO2022109743A1 (en) 2022-06-02
KR20230116833A (ko) 2023-08-04
EP4251654A4 (en) 2024-11-27

Similar Documents

Publication Publication Date Title
JP7068231B2 (ja) ＣＤ４０Ｌ特異的Ｔｎ３由来足場およびその使用方法
TWI585104B (zh) 基於vl和vhh可變區衍生物的高親和力抗聚集抗體
CN111094341A (zh) 在可变域和恒定域之间的肘区中具有功能域的抗体
CN112409480B (zh) 结合血清白蛋白的蛋白及其用途
CN113728005A (zh) Cd3特异性结合分子
JP2024504777A (ja) Ｍｕｌｔａｂｏｄｙ構築物、組成物および方法
US20230167185A1 (en) Cd40 binding protein
KR20230083316A (ko) Sars-cov-2를 표적화하는 폴리펩티드, 및 관련 조성물 및 방법
JP2023550191A (ja) Ｄｒ４および／またはｄｒ５を標的とするポリペプチドならびに関連する組成物および方法
WO2022253248A1 (zh) 抗cd3抗体变异体、融合蛋白及应用
US20250011397A1 (en) Modified multabody constructs, compositions, and methods targeting sars-cov-2
US20250002564A1 (en) Modified multabody constructs, compositions, and methods
JP2026500217A (ja) 結合分子
CN116615255A (zh) 靶向SARS-CoV-2的多肽及相关组合物和方法
WO2025256479A1 (zh) 一种融合蛋白及其用途
TW202336032A (zh) 白細胞介素2突變體以及含有其的複合物
WO2026026847A1 (zh) 一种b7-h3特异性抗体及其抗肿瘤应用
CN117915950A (zh) 一种多特异性抗体及其用途
HK40029066A (en) Antibodies with functional domains in the elbow region between variable and constant domain

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241122

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20241122

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251024

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20251029

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260123

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260323

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260424